Cargando…
The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650
SARS-CoV-2 is the cause of the worldwide outbreak of COVID-19 that has been characterized as a pandemic by the WHO. Since the first report of COVID-19 on December 31, 2019, 179,111 cases were confirmed in 160 countries/regions with 7426 deaths as of March 17, 2020. However, there have been no vaccin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190498/ https://www.ncbi.nlm.nih.gov/pubmed/32513514 http://dx.doi.org/10.1016/j.vaccine.2020.04.070 |
_version_ | 1783527691230642176 |
---|---|
author | Su, Qiu-dong Yi, Yao Zou, Ye-ning Jia, Zhi-yuan Qiu, Feng Wang, Feng Yin, Wen-jiao Zhou, Wen-ting Zhang, Shuang Yu, Peng-cheng Bi, Sheng-li Shen, Li-ping Wu, Gui-zhen |
author_facet | Su, Qiu-dong Yi, Yao Zou, Ye-ning Jia, Zhi-yuan Qiu, Feng Wang, Feng Yin, Wen-jiao Zhou, Wen-ting Zhang, Shuang Yu, Peng-cheng Bi, Sheng-li Shen, Li-ping Wu, Gui-zhen |
author_sort | Su, Qiu-dong |
collection | PubMed |
description | SARS-CoV-2 is the cause of the worldwide outbreak of COVID-19 that has been characterized as a pandemic by the WHO. Since the first report of COVID-19 on December 31, 2019, 179,111 cases were confirmed in 160 countries/regions with 7426 deaths as of March 17, 2020. However, there have been no vaccines approved in the world to date. In this study, we analyzed the biological characteristics of the SARS-CoV-2 Spike protein, Pro330-Leu650 (SARS-CoV-2-SPL), using biostatistical methods. SARS-CoV-2-SPL possesses a receptor-binding region (RBD) and important B (Ser438-Gln506, Thr553-Glu583, Gly404-Aps427, Thr345-Ala352, and Lys529-Lys535) and T (9 CD4 and 11 CD8 T cell antigenic determinants) cell epitopes. High homology in this region between SARS-CoV-2 and SARS-CoV amounted to 87.7%, after taking the biological similarity of the amino acids into account and eliminating the receptor-binding motif (RBM). The overall topology indicated that the complete structure of SARS-CoV-2-SPL was with RBM as the head, and RBD as the trunk and the tail region. SARS-CoV-2-SPL was found to have the potential to elicit effective B and T cell responses. Our findings may provide meaningful guidance for SARS-CoV-2 vaccine design. |
format | Online Article Text |
id | pubmed-7190498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71904982020-04-30 The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 Su, Qiu-dong Yi, Yao Zou, Ye-ning Jia, Zhi-yuan Qiu, Feng Wang, Feng Yin, Wen-jiao Zhou, Wen-ting Zhang, Shuang Yu, Peng-cheng Bi, Sheng-li Shen, Li-ping Wu, Gui-zhen Vaccine Article SARS-CoV-2 is the cause of the worldwide outbreak of COVID-19 that has been characterized as a pandemic by the WHO. Since the first report of COVID-19 on December 31, 2019, 179,111 cases were confirmed in 160 countries/regions with 7426 deaths as of March 17, 2020. However, there have been no vaccines approved in the world to date. In this study, we analyzed the biological characteristics of the SARS-CoV-2 Spike protein, Pro330-Leu650 (SARS-CoV-2-SPL), using biostatistical methods. SARS-CoV-2-SPL possesses a receptor-binding region (RBD) and important B (Ser438-Gln506, Thr553-Glu583, Gly404-Aps427, Thr345-Ala352, and Lys529-Lys535) and T (9 CD4 and 11 CD8 T cell antigenic determinants) cell epitopes. High homology in this region between SARS-CoV-2 and SARS-CoV amounted to 87.7%, after taking the biological similarity of the amino acids into account and eliminating the receptor-binding motif (RBM). The overall topology indicated that the complete structure of SARS-CoV-2-SPL was with RBM as the head, and RBD as the trunk and the tail region. SARS-CoV-2-SPL was found to have the potential to elicit effective B and T cell responses. Our findings may provide meaningful guidance for SARS-CoV-2 vaccine design. Elsevier Ltd. 2020-07-06 2020-04-30 /pmc/articles/PMC7190498/ /pubmed/32513514 http://dx.doi.org/10.1016/j.vaccine.2020.04.070 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Su, Qiu-dong Yi, Yao Zou, Ye-ning Jia, Zhi-yuan Qiu, Feng Wang, Feng Yin, Wen-jiao Zhou, Wen-ting Zhang, Shuang Yu, Peng-cheng Bi, Sheng-li Shen, Li-ping Wu, Gui-zhen The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |
title | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |
title_full | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |
title_fullStr | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |
title_full_unstemmed | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |
title_short | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 |
title_sort | biological characteristics of sars-cov-2 spike protein pro330-leu650 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190498/ https://www.ncbi.nlm.nih.gov/pubmed/32513514 http://dx.doi.org/10.1016/j.vaccine.2020.04.070 |
work_keys_str_mv | AT suqiudong thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT yiyao thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT zouyening thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT jiazhiyuan thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT qiufeng thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT wangfeng thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT yinwenjiao thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT zhouwenting thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT zhangshuang thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT yupengcheng thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT bishengli thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT shenliping thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT wuguizhen thebiologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT suqiudong biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT yiyao biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT zouyening biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT jiazhiyuan biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT qiufeng biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT wangfeng biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT yinwenjiao biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT zhouwenting biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT zhangshuang biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT yupengcheng biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT bishengli biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT shenliping biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 AT wuguizhen biologicalcharacteristicsofsarscov2spikeproteinpro330leu650 |